**EML4-ALK** Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report

Xinyu von Buttlar, MD, MS, a Joshua E. Reuss, MD, a,b Stephen V. Liu, MD, a,b Chul Kim, MD, MPH a,b,*

a MedStar Georgetown University Hospital, Department of Medicine, Washington, District of Columbia
b Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia

Received 5 March 2021; revised 13 April 2021; accepted 17 April 2021
Available online - 28 April 2021

**ABSTRACT**

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is the preferred frontline therapy for EGFR-mutant advanced NSCLC. However, despite its high initial response rates, multiple EGFR-independent mechanisms of resistance have been reported in patients receiving osimertinib. One such mechanism is the emergence of acquired, targetable oncogenic fusion events. It has been documented in other case reports that combination therapies can be efficacious in these scenarios. In our case report, we present a patient with EGFR-mutant advanced NSCLC who developed an acquired EML4-ALK rearrangement mediating resistance to osimertinib, which was overcome by using a combination of osimertinib and the ALK tyrosine kinase inhibitor alectinib.

© 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Keywords:** EGFR; ALK; Osimertinib; Case report

**Introduction**

EGFR tyrosine kinase inhibitor (TKI) therapy remains the standard frontline treatment for EGFR-mutant advanced NSCLC. Osimertinib, a third-generation EGFR TKI, improved both progression-free survival and overall survival when compared with first-generation EGFR TKIs,1 establishing it as the preferred frontline treatment option. Whereas osimertinib is an effective treatment for EGFR-mutant NSCLC, acquired resistance is expected.2 The mechanisms of resistance to frontline osimertinib are heterogenous and include secondary EGFR mutations, activation of alternative signaling pathways, and histologic transformation.2 Here, we report a case of an acquired ALK rearrangement mediating resistance to osimertinib that was overcome with a combination of osimertinib and the ALK TKI alectinib.

**Case Presentation**

A 78-year-old never-smoking woman presented with symptomatic left pleural effusion. A computed tomography (CT) scan was performed and revealed a lung mass in the left upper lobe (LUL). CT-guided biopsy was performed and pathological findings revealed poorly...
differentiated adenocarcinoma. Magnetic resonance imaging (MRI) of the brain was done and did not reveal any intracranial metastases. Positron emission tomography was done, which identified multiple pleural, osseous, and liver metastases. EGFR mutation analysis by Cobas real-time polymerase chain reaction (Roche diagnostics) revealed a sensitizing EGFR exon 19 deletion.

She enrolled in a clinical trial of osimertinib in combination with dasatinib, achieved a partial response, and was on the study for 20 months (Fig. 1). Blood-based next-generation sequencing (NGS) was performed 15 months into the clinical trial when initial signs of tumor growth were noted and revealed no detectable mutations (InVisionFirst-Lung, NeoGenomics, Research Triangle Park, NC). Brain MRI performed at the time of progression revealed no intracranial metastases. Subsequently, she received second-line osimertinib in combination with an EGFR monoclonal antibody on a clinical trial for 4 months before progression. Blood-based NGS obtained at progression revealed a KRAS G12V (variant allele frequency: 0.077%) without other genomic alterations including the original EGFR exon 19 deletion (InVisionFirst-Lung, NeoGenomics). She received third-line carboplatin plus pemetrexed with a mixed response followed by radiation to an oligoprogressive left adrenal gland lesion, which was given 3 months into chemotherapy. After four cycles of carboplatin (area under the curve 5) and pemetrexed (400 mg/m² except for cycle two when 500 mg/m² was given) given every 3 weeks, pemetrexed (400 mg/m²) was continued as maintenance therapy.

After 9 months of chemotherapy, the patient developed confusion. A brain MRI was performed and revealed numerous metastases; CT was also done and revealed extracranial progression. Circulating tumor DNA (ctDNA) testing (Guardant360 CDx, Redwood City, CA) was done, which revealed an EGFR exon 19 deletion (variant allele frequency: 11.5%), EGFR amplification (plasma copy number: 2.5), and TP53 mutations (Y163C, Y327*, R273H, splice site SNV). Pemetrexed was stopped and osimertinib 80 mg daily was restarted in the hopes of improved central nervous system (CNS) control. After 1 month, a repeat brain MRI revealed a mixed response, and osimertinib was increased to 160 mg daily. Another CT was done and revealed progression of extracranial disease. Tissue NGS (DNA- and RNA-based) (Caris Life Sciences, Phoenix, AZ) from a bronchoscopic biopsy was performed, exhibiting the original EGFR exon 19 deletion, an acquired EML4-ALK gene fusion (on RNA sequencing), NSD1 R375fs, and TP53 mutations. Osimertinib at a dose of 450 mg twice daily was added to osimertinib 80 mg daily. Alectinib 450 mg twice daily was chosen instead of the full dose (600 mg twice daily) owing to concerns about potential adverse effects of the combination. After 5 days, a brain MRI was performed and revealed a CNS response (Fig. 2). After 1 month, she was admitted with dyspnea and symptomatic anemia with a hemoglobin of 6.6 g/dL (her hemoglobin ranged from 7.3–7.9 g/dL before the admission). She was transfused and a source was not identified. A CT was performed and revealed a response in the left paramediastinal mass and pleural metastases (Fig. 3), but LUL opacities were noted. Treatment was held and she was treated with broad-spectrum antibiotics with improvement in the LUL opacities. An echocardiogram was performed, which revealed a normal ejection fraction, and coronavirus disease 2019 testing revealed negative results. On hospital day 13, she had an aspiration event in the setting of a known medical history of severe oral and pharyngeal dysmotility, leading to acute hypoxia. Subsequently, she was found to have had type II non-ST segment elevation myocardial infarction resulting in cardiogenic shock. Her clinical status declined, and she transitioned to comfort care.

Discussion

Here we describe a patient whose tumor developed an EML4-ALK rearrangement as a mechanism of resistance to osimertinib. It is unclear when the EML4-ALK rearrangement developed in this patient. Although the three ctDNA tests obtained around the time of disease...
progression on first-, second-, and third-line treatment did not exhibit the \textit{EML4-ALK} rearrangement, given the moderate sensitivity of liquid biopsy, it is possible that the \textit{EML4-ALK} rearrangement developed earlier in the course of treatment. The second ctDNA test revealed a \textit{KRAS} G12V mutation. It is unclear whether the \textit{KRAS} mutation represents a mechanism of resistance to osimertinib, clonal hematopoiesis of indeterminate potential, or a sequencing error.

More importantly, the combination of osimertinib and alectinib resulted in a response of the thoracic disease, suggesting potential clinical efficacy of the combination in this setting. It is difficult to determine whether the decrease in size of brain lesions was because of the higher dose osimertinib 160 mg daily or the combination of osimertinib and alectinib, as both have good CNS penetration. The combination treatment was associated with low-grade diarrhea and anemia but was otherwise

\textbf{Figure 2.} (\textit{A, C}) The brain MRI obtained while the patient was taking osimertinib 80 mg daily revealed numerous brain lesions. Shortly after the brain MRI was obtained, osimertinib was increased to 160 mg daily. Subsequently, treatment was switched to osimertinib 80 mg daily plus alectinib 450 mg daily. (\textit{B, D}) Brain MRI obtained 5 days after initiation of the combination therapy revealed shrinkage of brain lesions. MRI, magnetic resonance imaging.
well tolerated. It is unlikely that the treatment was the culprit for the patient’s cardiac events given the normal ejection fraction at the time of admission and the temporal association between the aspiration event resulting in acute hypoxia and the development of the cardiac events.

Fusion events have been described as an EGFR-independent mechanism of acquired resistance in patients with EGFR-mutant NSCLC receiving osimertinib.2 These oncogenic fusion events likely behave as oncogenic drivers, and reported examples include FGFR3-TACC3, RET-ERC1, CCDC6-RET, NTRK1-TPM3, GOPC-ROS1, AGK-BRAF, ESYT2-BRAF, SPTBN1-ALK, PLEKHA7-ALK, EML4-ALK,2,3 and STRN-ALK.4

Acquired EML4-ALK rearrangements have been identified in patients receiving an EGFR TKI including osimertinib3–5 (Table 1). In a case report of two patients with ALK fusion-mediated resistance, osimertinib was combined with crizotinib or alectinib, and the combination provided benefit to both patients.4 A separate case report documented resistance to gefitinib owing to EML4-ALK rearrangement.5 The patient received gefitinib plus crizotinib, osimertinib plus crizotinib (owing to the development of EGFR T790M), and osimertinib plus brigatinib (owing to the development of secondary ALK mutations), suggesting that serial molecular testing could guide the choice of specific targeted therapy agents. In another case report, an acquired STRN-ALK fusion was identified as a resistance mechanism to osimertinib, and switching the treatment regimen to gefitinib and crizotinib combination achieved a partial response.4 The true activity of these combinations is difficult to ascertain, acknowledging selection bias associated with case reports. Our case is unique in that ALK fusion occurred in the setting of the first-line use of osimertinib. Notably, the patient’s ALK fusion was detected on tissue NGS, but not on ctDNA testing, highlighting the use of tissue-based RNA sequencing for detection of fusion events and the need for highly sensitive blood-based NGS assays.

Conclusion
Our case adds to the limited body of literature illustrating ALK rearrangement as a mechanism of resistance to osimertinib in advanced EGFR-mutant NSCLC, and the addition of ALK TKI therapy to osimertinib could serve as a viable therapeutic strategy in this setting. A biomarker-directed phase 2 platform study in patients with advanced NSCLC whose disease has progressed on frontline osimertinib therapy, ORCHARD (NCT03944772), will assess the combination of osimertinib and alectinib in patients with EGFR-mutant NSCLC whose disease progresses on frontline osimertinib and will provide more information on the safety and efficacy of the combination.

Acknowledgments
The authors received no specific funding for this work. Informed consent for publication was obtained from the patient’s family.
Table 1. Reported Cases of Osimertinib Resistance Owing to ALK Fusion Treated With ALK Inhibitor Therapy

| Case | Age | Sex | Smoking | Organs involved | Systemic therapies before ALK fusion detection | ALK fusion detected | Other genomic alterations | Treatment regimen | Duration of treatment | Tumor response | Adverse events |
|------|-----|-----|---------|----------------|-----------------------------------------------|--------------------|--------------------------|------------------|---------------------|---------------|---------------|
| 1    | 65  | F   | Former (9-pack-year) | Lung, liver | Erlotinib osimertinib/necitumumab | EML4-ALK | EGFR exon 19 deletion | Osimertinib 80 mg QD/crizotinib 200 mg twice daily | 6 mo<sup>a</sup> | Stable disease | No reported toxicities |
| 2    | 68  | F   | Never smoker | Lung, brain | Erlotinib osimertinib | EML4-ALK | EGFR L858R/EGFR T790M | Osimertinib 80 mg QD/alectinib 300 mg twice daily | 1 mo<sup>a</sup> | Stable disease<sup>b</sup> | No reported toxicities |
| 3<sup>5</sup> | 43  | M   | Never smoker | Lung, brain, adrenal gland, liver | Gefitinib | EML4-ALK | EGFR exon 19 deletion | GC | 5 mo with GC | Partial response | Rash with GC, OC, Rash and diarrhea with OB |
| 4<sup>d</sup> | 43  | M   | Current smoker | Lung, liver, bone | Gefitinib osimertinib | STRN-ALK | EGFR exon 19 deletion | GC Osimertinib 80 mg QD/alectinib 450 mg twice daily | 6 mo<sup>c</sup> | Partial response | Rash |
| 5 (Current Case Report) | 81  | F   | Never smoker | Lung, brain, bone, liver | Gefitinib osimertinib | EML4-ALK | EGFR exon 19 deletion | Osimertinib/dasatinib Osimertinib/EGFR monoclonal antibody Carboplatin/pemetrexed | 1 mo | Partial response | Anemia, diarrhea |

<sup>a</sup>Ongoing treatment at the time of writing.
<sup>b</sup>A – 25% reduction by RECIST version 1.1.
<sup>c</sup>NSD1 R375fs TP53 mutations

F, female; GC, Gefitinib/crizotinib; M, male; OB, osimertinib/brigatinib; OC, osimertinib/crizotinib; QD, once daily; RECIST, Response Evaluation Criteria in Solid Tumors.1
References

1. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. *N Engl J Med*. 2020;382:41-50.

2. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. *Br J Cancer*. 2019;121:725-737.

3. Ofni M, Somwar R, Rekhtman N, et al. Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers. *JCO Precis Oncol*. 2018;2:PO.18.00126.

4. Zhou C, Zeng L, Zhang Y, Yang N. Responder of gefitinib plus crizotinib in osimertinib failure EGFR-mutant NSCLC-resistant with newly identified STRN-ALK by next-generation sequencing. *J Thorac Oncol*. 2019;14:143-144.

5. Hu Y, Xiao L, Yang N, Zhang Y. Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient. *Thorac Cancer*. 2019;10:1252-1255.